CVS Partially Dropping Top-Selling Drug Humira In Favor Of Cheaper Biosimilars
The drug generated $21 billion for AbbVie in 2022 and is projected to drop to $9 billion in sales this year.
Source: forbes.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Replace Abbvie. Real-time updates on events, politics, business and more.